WASHINGTON, DC
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)KIDNEY CARE PARTNERS INC CO FEDERAL HEALTH POLICY STRATEGIES, founded in 2003, is a community nonprofit in the Diseases & Disorders sector that reported $1.9M in total revenue in fiscal year 2023. Revenue surged 32% from the prior year, signaling strong growth momentum. The organization ran a surplus of $422K, a strong 22% operating margin.
TO PROMOTE THE COMMON GOOD AND GENERAL WELFARE OF ALL AMERICANS BY 1)PROMOTING RESPONSIBLE GOVERNMENT PRACTICES THROUGH PUBLIC POLICIES THAT ASSURE HIGH QUALITY KIDNEY CARE TREATMENT FOR PEOPLE WHO HAVE ADVANCED KIDNEY DISEASE, 2)PROMOTING RESPONSIBLE AND EFFICIENT MEDICARE REFORM RELATING TO DIALYSIS AND TO ENSURE PATIENTS HAVE ACCESS TO QUALITY OF CARE.
KIDNEY CARE PARTNERS PRIMARY ACTIVITES ARE TO PROMOTE QUALITY RENAL CARE AND TO IMPROVE REIMBURSEMENT FOR END STAGE RENAL DISEASE (ESRD) PATIENTS IN THE US. IN 2022, KCP ALSO SOUGHT TO IMPROVE...
KIDNEY CARE PARTNERS PRIMARY ACTIVITES ARE TO PROMOTE QUALITY RENAL CARE AND TO IMPROVE REIMBURSEMENT FOR END STAGE RENAL DISEASE (ESRD) PATIENTS IN THE US. IN 2022, KCP ALSO SOUGHT TO IMPROVE POLICIES AND PAYMENT FOR NEW TECHNOLOGIES IN THE ESRD SYSTEM. KCP ACTIVITIES INCLUDE OUTREACH TO HEALTH & HUMAN SERVICES, THE CENTER FOR MEDICARE SERVICES, THE WHITE HOUSE, MEDPAC, CONGRESS AND OTHER AGENCIES AS REQUIRED. WE UNDERTAKE GRASSROOTS ACTIVITIES, PUBLIC EDUCATION AND AWARENESS, MARKETING, LOBBYING AND OTHER ADVOCACY ACTIVITIES. OUR CORE ACTIVITES FOCUS ON INFUENCING MEDICARE POLICIES RELATED TO PAYMENT AND QUALITY MEASUREMENT FOR THE ESRD PROGRAM. WE PRIMARILY WORK WITH THE CONGRESS AND HHS/CMS ON THESE EFFORTS SEEKING TO IMPROVE VARIOUS ASPECTS OF THE ESRD PAYMENT SYSTEM, RESEARCH, SEARCH QUALITY MEASUREMENT, LICENSE AND CERTIFICATION OF ESRD FACILITIES, MEDICARE ADVANTAGE PAYMENT AND BENEFIT DESIGN AND COVERAGE, AND ACCESS TO COVERAGE FOR ESRD BENEFICIARIES IN THE PRIVATE SECTOR. OUR EFFORTS REQUIRE ADVOCACY RESOURCES AS WELL AS ANALYSIS OF GOVERNMENT AND PRIVATE SECTOR DATA. WE TARGET KEY LEADERSHIP IN THE HOUSE, SENATE, WH, HHS, CMS, AND OTHER AGENCIES. WE FORMULATE COMMUNMITY COMMENTS ON PROPOSED SOLUTIONS AND LEGISLATIVE ERO PROPOSALS AS WELL AS ADVANCING OUR OWN COMMUNITY LEGISLATIVE AND REGULATORY POLICY.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $1,947,138 | $1,473,804 | +0.3% |
| Expenses | $1,525,093 | $1,946,424 | -0.2% |
| Net Income | $422,045 | $-472,620 | -1.9% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| GENE BLANKENSHIP | DIALYSEDIRECT | 2.00 |
Director
|
$0 | $0 | $0 |
| BILL POIRIER | GREENFIELD HS | 2.00 |
Director
|
$0 | $0 | $0 |
| MO ALZUBAIDI | RENAL P.A. | 2.00 |
Director
|
$0 | $0 | $0 |
| STACEY FAHRNER | FRESENIUS M.C. | 2.00 |
Director
|
$0 | $0 | $0 |
| CHERILYN CEPRIANO | KC COUNCIL | 2.00 |
Director
|
$0 | $0 | $0 |
| CHRIS LEIBUNDGUTH | BAXTER INTL | 2.00 |
Director
|
$0 | $0 | $0 |
| SARAH HAMLETT | CSL VIFOR | 0.00 |
Director
|
$0 | $0 | $0 |
| DONNA BEDNARSKI | NEPHROLOGY NA | 2.00 |
Director
|
$0 | $0 | $0 |
| ERIN MISTRY | CORMEDIX INC | 2.00 |
Director
|
$0 | $0 | $0 |
| BABAJIDE SALAKO | DIALYSIS CARE | 2.00 |
Director
|
$0 | $0 | $0 |
| J GANESH BHAT | ATLANTIC DMS | 2.00 |
Director
|
$0 | $0 | $0 |
| DAN WEINER | A S NEPHROLOGY | 2.00 |
Director
|
$0 | $0 | $0 |
| GARY ROBINSON | CENTER DIALYSIS | 2.00 |
Director
|
$0 | $0 | $0 |
| JEFFREY SILBERZWEIG | ROGOSIN INSTITU | 2.00 |
Director
|
$0 | $0 | $0 |
| JOELLE THORNHILL | DAVITA INC | 2.00 |
Director
|
$0 | $0 | $0 |
| KATHY HOULE | NEPHROLOGY NURS | 2.00 |
Director
|
$0 | $0 | $0 |
| POOJA DESAI | ASTRAZENECA | 2.00 |
Director
|
$0 | $0 | $0 |
| LAVARNE BURTON | AMERICAN KIDNEY | 2.00 |
Director
|
$0 | $0 | $0 |
| CHRIS GOODWIN | GLAXOSMITHKLEIN | 0.00 |
Director
|
$0 | $0 | $0 |
| SHALABH GUPTA | UNICYCIVE THERA | 0.00 |
Director
|
$0 | $0 | $0 |
| PAUL PEREIRA | ARDELYX | 2.00 |
Director
|
$0 | $0 | $0 |
| MICHAEL SOMERS | A.S. OF PEDIATR | 2.00 |
Director
|
$0 | $0 | $0 |
| PATRICE SMITH | SATELLITE HEALT | 2.00 |
Director
|
$0 | $0 | $0 |
| ROB BOMSTAD | RENAL HEALTHCAR | 2.00 |
Director
|
$0 | $0 | $0 |
| SARA FROELICH | AKEBIA THERAPEU | 2.00 |
Director
|
$0 | $0 | $0 |
| SCOTT TERRILLION | CARA THERAPEUTI | 2.00 |
Director
|
$0 | $0 | $0 |
| FRANCINE ATTRILL | US RENAL CARE | 2.00 |
Director
|
$0 | $0 | $0 |
| WADE DELK | NORTH AMERICAN | 2.00 |
Director
|
$0 | $0 | $0 |
| MAHESH KRISHAN | KCP CHAIR | 2.00 |
Officer
|
$0 | $0 | $0 |
| COLIN ROSKEY | Executive Dir. | 40.00 |
Officer
|
$0 | $0 | $0 |
| JOHN BUTLER | PAST CHAIR | 2.00 |
Officer
|
$0 | $0 | $0 |
| LORI HARTWELL | KCP TREASURER | 2.00 |
Officer
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $1,947,138 | $1,525,093 | $2,124,276 | $422,045 |
| 2022 | $1,473,804 | $1,946,424 | $959,763 | $-472,620 |
| 2021 | $1,130,158 | $1,463,128 | $1,501,158 | $-332,970 |
| 2020 | $2,005,874 | $1,492,979 | $1,295,758 | $512,895 |
Compare KIDNEY CARE PARTNERS INC CO FEDERAL HEALTH POLICY STRATEGIES with other nonprofits in District of Columbia and across the country.